Nivolumab

證據等級: L5

預測適應症: 10 個

Nivolumab: From Melanoma to Non-Cutaneous Melanoma

One-Sentence Summary

Nivolumab is an anti-PD-1 immune checkpoint inhibitor whose first approved use was in melanoma treatment. The TxGNN model predicts it may also be effective for Non-Cutaneous Melanoma (rare melanoma subtypes such as mucosal, ocular, and metastatic-site presentations), with 50 clinical trials and 8 publications currently supporting this direction — though this represents an extension of an already-validated mechanism rather than a true cross-disease repurposing.

Quick Overview

Item	Content
Original Indication	Not documented in this evidence pack (no Danish marketing authorisation on file); Nivolumab’s known first approved oncology indication is (cutaneous) melanoma
Predicted New Indication	Non-Cutaneous Melanoma
TxGNN Prediction Score	98.41%
Evidence Level	L1
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is flagged as a data gap in this evidence pack (DG002). However, Nivolumab’s pharmacological class is well established in the broader literature and is reflected in the underlying prediction rationale: it is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody, an immune checkpoint inhibitor that blocks PD-1/PD-L1 signalling to restore T-cell-mediated anti-tumour immunity.

Melanoma — including cutaneous forms — was among Nivolumab’s earliest approved oncology indications. “Non-cutaneous melanoma” is not a distinct disease but a grouping of rarer melanoma presentations (e.g. mucosal, ocular/uveal, metastatic-site melanoma) that share the same underlying tumour biology and PD-L1 expression pathways as cutaneous melanoma. Because the checkpoint-blockade mechanism does not depend on the anatomical site of the primary lesion, extending Nivolumab to non-cutaneous subtypes is mechanistically a natural and low-risk extension of an already-validated therapeutic principle, rather than a repurposing into an unrelated disease area.

This is corroborated by the supporting evidence: several trials and cohort studies directly enrol non-cutaneous/rare melanoma subtypes (e.g. mucosal, acral, ocular, mediastinal, anorectal presentations) alongside standard cutaneous melanoma populations, generally showing continued — though sometimes attenuated — clinical activity.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03635983	Phase 3	Completed	783	NKTR-214 + nivolumab vs. nivolumab alone in previously untreated unresectable/metastatic melanoma; largest completed head-to-head trial in this pack
NCT04114136	Phase 2	Recruiting	72	Anti-PD-1 mAb (pembrolizumab/nivolumab) as standard-of-care arm across melanoma and other solid tumours, testing metabolic modulators to reverse tumour hypoxia
NCT02990611	N/A (non-interventional)	Completed	1087	National prospective real-world study of nivolumab monotherapy or with ipilimumab in advanced and adjuvant melanoma settings
NCT04157985	Phase 3	Completed	161	Randomised trial evaluating optimal duration of PD-1/PD-L1 inhibitor therapy in advanced solid tumours including melanoma
NCT05116202	Phase 1b/2	Completed	110	Morpheus-Melanoma umbrella study evaluating multiple nivolumab-based treatment combinations in resectable/metastatic melanoma
NCT03325257	N/A (follow-up cohort)	Completed	350	Two-year follow-up of melanoma patients treated with nivolumab during the French early-access (ATU) programme
NCT03033576	Phase 2	Completed	94	Nivolumab ± ipilimumab in advanced melanoma refractory to prior anti-PD-1/PD-L1 therapy
NCT02910700	Phase 2	Active, not recruiting	52	Triplet combinations of nivolumab with BRAF/MEK inhibitors in BRAF-mutated metastatic melanoma
NCT04146324	N/A (observational)	Completed	150	Prospective real-world study of adjuvant nivolumab in resected melanoma (Australia), 5-year follow-up
NCT04165967	Phase 1	Completed	9	TIL adoptive transfer combined with nivolumab in advanced melanoma failing prior immunotherapy

Literature Evidence

PMID	Year	Type	Journal	Key Findings
26841210	2016	Cohort	J Eur Acad Dermatol Venereol	Single-institution comparison of cutaneous vs. non-cutaneous melanoma treated with nivolumab
30510916	2018	Cohort	Frontiers in Oncology	Serum soluble CD163 as a predictive biomarker of nivolumab effectiveness in advanced melanoma
37887546	2023	Cohort	Current Oncology	Retrospective comparison of anti-PD-1 ± ipilimumab outcomes by age group in advanced melanoma
34176837	2022	Case Report	Internal Medicine (Tokyo)	Mediastinal (non-cutaneous) malignant melanoma with marked shrinkage on nivolumab monotherapy
40236344	2025	Case Report	Cureus	Colonic metastasis from melanoma managed with immunotherapy including nivolumab
41774417	2025	Case Report	Pigment Cell & Melanoma Research	Epidermotropic metastatic melanoma continuing to form new lesions despite adjuvant nivolumab
30549256	2019	Case Report	Int J Rheum Dis	Association between rheumatic immune-related adverse events and treatment response to PD-1 inhibitors
28171845	2017	Case Report	Int J Surg Case Rep	First reported case of metastatic anorectal amelanotic (non-cutaneous) melanoma responding to nivolumab

Denmark Market Information

Nivolumab currently has no marketing authorisation on file in Denmark (0 authorisations recorded; market status: not marketed). No product name, dosage form, or approved indication text is available from Danish regulatory sources for this evidence pack.

Cytotoxicity

Nivolumab is an immune checkpoint inhibitor (anti-PD-1 monoclonal antibody) and is classified as antineoplastic based on its established oncology indication and drug class, though it is not a conventional cytotoxic agent.

Item	Content
Cytotoxicity Classification	Immunotherapy (anti-PD-1 immune checkpoint inhibitor)
Myelosuppression Risk	Low — mechanism does not directly target bone marrow; classic cytotoxic myelosuppression is not the primary concern
Emetogenicity Classification	Low
Monitoring Items	Immune-related adverse events (irAEs): thyroid function, liver function (LFTs), renal function, pulmonary status (pneumonitis), colitis symptoms, skin reactions, and cardiac monitoring — literature in this pack documents nivolumab-associated myocarditis and rhabdomyolysis cases
Handling Protection	Standard biologic/monoclonal antibody handling precautions apply; conventional cytotoxic drug handling protocols are not required

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. This evidence pack has no key warnings, contraindications, or drug-drug interaction data on file for Nivolumab (a blocking data gap, DG001, has been logged for missing Danish label information).

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The underlying anti-PD-1 mechanism is already clinically validated in melanoma, including a completed Phase 3 head-to-head trial (NCT03635983, n=783) and a large real-world cohort (n=1087), supporting L1-level evidence overall. However, this is an extension within an already-approved disease area rather than a novel repurposing, and formal safety/label data for the Danish market is entirely missing (blocking gap).

To proceed, the following is needed:

Danish/EU Summary of Product Characteristics (SmPC) — resolves blocking data gap DG001
Confirmed mechanism-of-action documentation from DrugBank — resolves DG002
Subtype-specific efficacy data isolating non-cutaneous melanoma outcomes from mixed-population trials
A structured immune-related adverse event monitoring plan given the myocarditis and rhabdomyolysis signals noted in the literature review
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.